Lifirafenib Plus Mirdametinib Shows Tolerable Safety in BRAF/KRAS Mutant Advanced Solid Tumors
April 17, 2023 12:29 pmby Nichole Tucker
The success of BRAF/MEK combinations has led to the discovery of safety and preliminary activity with an investigational pan-RAF/MEK combination.
The investigational combination of lifirafenib (BGB-283) and mirdametinib (PD-0325901) has shown a favorable safety profile, as well … Read more